What is Gradient Denervation Technologies?
Gradient Denervation Technologies is a Paris-based medical device company dedicated to pioneering a minimally invasive, ultrasound-based system designed to treat pulmonary hypertension, particularly in patients suffering from left-sided heart disease. Their proprietary Gradient Denervation System employs therapeutic ultrasound energy to target and ablate nerves surrounding the pulmonary artery. This innovative approach addresses a critical unmet clinical need for a patient demographic with limited therapeutic alternatives. The company's technological foundation is built upon intellectual property originating from Stanford University, with the overarching goal of fundamentally reshaping the treatment paradigm for pulmonary hypertension and enhancing patient outcomes.
How much funding has Gradient Denervation Technologies raised?
Gradient Denervation Technologies has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Thuja Capital, Asabys Partners, and Sofinnova Partners
Key Investors in Gradient Denervation Technologies
Thuja Capital
Thuja Capital is a prominent early-stage venture capital firm that concentrates on investing in groundbreaking life science companies across Europe, aiming to drive transformative impacts in healthcare through deep sector expertise and a robust network.
Asabys Partners
Asabys Partners is an investment firm based in Barcelona that focuses on fostering breakthrough innovation in healthcare and life sciences, investing in highly innovative and transformative technologies to improve patients' lives.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, acting as a hands-on company builder across the entire value chain of life sciences investments.
What's next for Gradient Denervation Technologies?
The substantial enterprise-level funding secured by Gradient Denervation Technologies positions the company for accelerated growth and market penetration. This strategic investment is anticipated to fuel the advancement of their Gradient Denervation System through critical development phases, clinical trials, and eventual commercialization. The company's focus on a significant unmet medical need, coupled with strong backing from specialized life science investors, suggests a trajectory aimed at establishing a new standard of care in pulmonary hypertension treatment. Future developments will likely involve scaling manufacturing capabilities, expanding clinical evidence, and navigating regulatory pathways to bring this transformative technology to patients worldwide.
See full Gradient Denervation Technologies company page
